» Articles » PMID: 39187388

Ketamine and Major Ketamine Metabolites Function As Allosteric Modulators of Opioid Receptors

Overview
Journal Mol Pharmacol
Date 2024 Aug 26
PMID 39187388
Authors
Affiliations
Soon will be listed here.
Abstract

Ketamine is a glutamate receptor antagonist that was developed over 50 years ago as an anesthetic agent. At subanesthetic doses, ketamine and some metabolites are analgesics and fast-acting antidepressants, presumably through targets other than glutamate receptors. We tested ketamine and its metabolites for activity as allosteric modulators of opioid receptors expressed as recombinant receptors in heterologous systems and with native receptors in rodent brain; signaling was examined by measuring GTP binding, -arrestin recruitment, MAPK activation, and neurotransmitter release. Although micromolar concentrations of ketamine alone had weak agonist activity at opioid receptors, the combination of submicromolar concentrations of ketamine with endogenous opioid peptides produced robust synergistic responses with statistically significant increases in efficacies. All three opioid receptors (, , and ) showed synergism with submicromolar concentrations of ketamine and either methionine-enkephalin (Met-enk), leucine-enkephalin (Leu-enk), and/or dynorphin A17 (Dyn A17), albeit the extent of synergy was variable between receptors and peptides. -ketamine exhibited higher modulatory effects compared with -ketamine or racemic ketamine, with ∼100% increase in efficacy. Importantly, the ketamine metabolite 6-hydroxynorketamine showed robust allosteric modulatory activity at opioid receptors; this metabolite is known to have analgesic and antidepressant activity but does not bind to glutamate receptors. Ketamine enhanced potency and efficacy of Met-enkephalin signaling both in mouse midbrain membranes and in rat ventral tegmental area neurons as determined by electrophysiology recordings in brain slices. Taken together, these findings support the hypothesis that some of the therapeutic effects of ketamine and its metabolites are mediated by directly engaging the endogenous opioid system. SIGNIFICANCE STATEMENT: This study found that ketamine and its major biologically active metabolites function as potent allosteric modulators of , , and opioid receptors, with submicromolar concentrations of these compounds synergizing with endogenous opioid peptides, such as enkephalin and dynorphin. This allosteric activity may contribute to ketamine's therapeutic effectiveness for treating acute and chronic pain and as a fast-acting antidepressant drug.

Citing Articles

Beyond NMDA Receptors: A Narrative Review of Ketamine's Rapid and Multifaceted Mechanisms in Depression Treatment.

Antos Z, Zukow X, Bursztynowicz L, Jakubow P Int J Mol Sci. 2025; 25(24.

PMID: 39769420 PMC: 11728282. DOI: 10.3390/ijms252413658.

References
1.
Slosky L, Caron M, Barak L . Biased Allosteric Modulators: New Frontiers in GPCR Drug Discovery. Trends Pharmacol Sci. 2021; 42(4):283-299. PMC: 9797227. DOI: 10.1016/j.tips.2020.12.005. View

2.
Wulf H, Browne C, Zarate C, Lucki I . Mediation of the behavioral effects of ketamine and (2R,6R)-hydroxynorketamine in mice by kappa opioid receptors. Psychopharmacology (Berl). 2022; 239(7):2309-2316. DOI: 10.1007/s00213-022-06118-4. View

3.
Zhang F, Hillhouse T, Anderson P, Koppenhaver P, Kegen T, Manicka S . Opioid receptor system contributes to the acute and sustained antidepressant-like effects, but not the hyperactivity motor effects of ketamine in mice. Pharmacol Biochem Behav. 2021; 208:173228. DOI: 10.1016/j.pbb.2021.173228. View

4.
Zheng H, Chu J, Qiu Y, Loh H, Law P . Agonist-selective signaling is determined by the receptor location within the membrane domains. Proc Natl Acad Sci U S A. 2008; 105(27):9421-6. PMC: 2453714. DOI: 10.1073/pnas.0802253105. View

5.
Gupta A, Devi L, Gomes I . Potentiation of μ-opioid receptor-mediated signaling by ketamine. J Neurochem. 2011; 119(2):294-302. PMC: 3856727. DOI: 10.1111/j.1471-4159.2011.07361.x. View